• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Cubist Pharmaceuticals, Inc. - Product Pipeline Review - 2012 Product Image

Cubist Pharmaceuticals, Inc. - Product Pipeline Review - 2012

  • ID: 2135994
  • May 2012
  • 111 pages
  • Global Markets Direct

Cubist Pharmaceuticals, Inc. – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “Cubist Pharmaceuticals, Inc. - Product Pipeline Review - 2012” provides data on the Cubist Pharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Cubist Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Cubist Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Cubist Pharmaceuticals, Inc. - Brief Cubist Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Cubist Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage READ MORE >

Note: Product cover images may vary from those shown



List of Tables
List of Figures
Cubist Pharmaceuticals, Inc. Snapshot
Cubist Pharmaceuticals, Inc. Overview
Key Information
Key Facts
Cubist Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
Cubist Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Cubist Pharmaceuticals, Inc. – Pipeline Products Glance
Cubist Pharmaceuticals, Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Cubist Pharmaceuticals, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Cubist Pharmaceuticals, Inc. – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Cubist Pharmaceuticals, Inc. – Drug Profiles
ADL6906
Product Description
Mechanism of Action
R&D Progress
Bacterial Infections Program
Product Description
Mechanism of Action
R&D Progress
CAMORs
Product Description
Mechanism of Action
R&D Progress
CB-183,315
Product Description
Mechanism of Action
R&D Progress
CB-625
Product Description
Mechanism of Action
R&D Progress
CXA-201 + Metronidazole
Product Description
Mechanism of Action
R&D Progress
CXA201
Product Description
Mechanism of Action
R&D Progress
Cubist Pharmaceuticals, Inc. – Pipeline Analysis
Cubist Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
Cubist Pharmaceuticals, Inc. – Pipeline Products By Target
Cubist Pharmaceuticals, Inc. – Pipeline Products by Route of Administration
Cubist Pharmaceuticals, Inc. – Pipeline Products By Mechanism of Action
Cubist Pharmaceuticals, Inc. – Recent Pipeline Updates
Cubist Pharmaceuticals, Inc. - Dormant Projects
Cubist Pharmaceuticals, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
ADL5747
ADL5859
CB-182,804
HepeX-B
Cubist Pharmaceuticals, Inc. – Company Statement
Cubist Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Cubist Pharmaceuticals, Inc., Recent Developments
Cubist Pharmaceuticals, Inc.- Press Release
Apr 17, 2012: Cubist Announces Positive Results From ENTEREG Phase IV Study In Patients Undergoing Radical Cystectomy
Feb 09, 2012: Cubist Receives CUBICIN Paragraph IV Notice Letter
Jan 10, 2012: Cubist And Hydra Announce Plans To Begin Phase I Clinical Trial For Novel TRPA1 Modulator To Treat Acute Pain
Dec 14, 2009: Cubist Pharmaceuticals To Acquire Calixa Therapeutics
Dec 11, 2009: Trial Date Set for CUBICIN Patent Litigation
Nov 13, 2009: Adolor Corporation Initiates Clinical Testing Of ADL7445 For Treatment Of Opioid Bowel Dysfunction
Sep 15, 2009: Calixa Therapeutics To Make Multiple Presentations On CXA-101 And CXA-101/Tazobactam At The 49th Annual Interscience Conference On Antimicrobial Agents And Chemotherapy
Jul 01, 2009: Calixa Therapeutics Announces Initiation Of Phase 2 Clinical Trial Of Its Antibiotic, CXA-101, In Patients With Complicated Urinary Tract Infections
Mar 27, 2009: Cubist Pharmaceuticals Initiates Phase 2 Trial for Therapy to Reduce Blood Loss During Surgery
Mar 24, 2009: Calixa Therapeutics Announces Positive Phase I Results For CXA-101, A Novel Intravenous Cephalosporin Antibiotic With Excellent Anti-Pseudomonal Activity
Feb 17, 2009: Phase I Trial Begins For Investigational New Drug For MDR Gram-Negative Infections
Feb 13, 2009: Cubist Pharmaceuticals Announces Start Of First-in-Human Clinical Trial For Investigational New Drug For Clostridium difficile Infections
Jan 05, 2009: Cubist Pharmaceuticals Announces Submission Of 2 INDs Targeting Serious Infections Caused By MDR Gram-Negative Pathogens And By Clostridium Difficile
Jan 05, 2009: Cubist Pharmaceuticals, the Developer of CUBICIN, Announces Submission of 2 INDs Targeting Serious Infections Caused by MDR Gram-negative Pathogens and by Clostridium difficile
Jan 05, 2009: Cubist Pharmaceuticals Announces Submission Of 2 INDs Targeting Serious Infections Caused By MDR Gram-Negative Pathogens And By Clostridium Difficile
Financial Deals Landscape
Cubist Pharmaceuticals, Inc., Deals Summary
Cubist Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
Adolor Reacquires Rights Of ENTEREG From GlaxoSmithKline
Cubist Pharma Acquires 2% Royalty Stream Of CUBICIN From Eli Lilly
Venture Financing
FORMA Therapeutics Secures Additional $3 Million In Series B Financing Round
Calixa Therapeutics Secures $30 Million In Series A Financing
Illumigen Biosciences Secures $12 Million In Venture Financing
Illumigen Biosciences Secures $5 Million In Series B Financing
Partnerships
Adolor Enters Into Licensing And Co-Development Agreement With Pfizer
Optimer Pharma Enters Into Co-Promotion Agreement With Cubist Pharma
Evotec Extends Research Agreement With Cubist Pharma
Cubist Pharma Enters Into Co-Development Agreement With Hydra Biosciences
Evotec Enters Into Research Agreement With Cubist Pharma
Beactica Enters Into Co-Development Agreement With Cubist Pharma
FORMA Therapeutics Enters Into Co-Development Agreement With Cubist Pharma
Cubist Pharma Enters Into Co-Development Agreement With Alnylam
Cubist Pharma Enters Into Co-Promotion Agreement With AstraZeneca
deCODE biostructures Enters Into Research Agreement With Cubist Pharma
Cubist Pharma Enters Into Co-Marketing Agreement With Kuhnil Pharma
Adolor Enters Into Co-Promotion Agreement With GlaxoSmithKline
Adolor Amends Collaboration Agreement With GlaxoSmithKline
Licensing Agreements
Motac Neuroscience Enters Into Licensing Agreement With Adolor
Adolor Enters Into Licensing Agreement With Eli Lilly
Cubist Pharma Enters Into Licensing Agreement With Dyax
Cubist Pharma Enters Into Licensing Agreement With Merck
AstraZeneca Enters Into Licensing Agreement With Cubist Pharma
Cubist Pharma Enters Into Licensing Agreement With XTL BioPharma
Equity Offering
Adolor Files Registration Statement For Public Offering Of $100 Million
Adolor Completes Public Offering Of $143.75 Million
Cubist Pharma Completes Public Offering Of $120 Million
Debt Offering
Cubist Pharma Completes Private Placement Of Convertible Senior Notes Due 2017 For $450 Million
Cubist Pharma Completes Public Offering Of 2.25% Convertible Notes For $350 Million
Acquisition
Cubist Pharma Completes Acquisition Of Adolor For $415 Million
Cubist Pharma Acquires Calixa Therapeutics
Cubist Pharma Acquires Illumigen Biosciences
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Cubist Pharmaceuticals, Inc., Key Information
Cubist Pharmaceuticals, Inc., Key Facts
Cubist Pharmaceuticals, Inc. – Pipeline by Indication, 2012
Cubist Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2012
Cubist Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2012
Cubist Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, 2012
Cubist Pharmaceuticals, Inc. – Phase III, 2012
Cubist Pharmaceuticals, Inc. – Phase II, 2012
Cubist Pharmaceuticals, Inc. – Phase I, 2012
Cubist Pharmaceuticals, Inc. – Pre-Clinical, 2012
Cubist Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, 2012
Cubist Pharmaceuticals, Inc. - Pipeline By Target, 2012
Cubist Pharmaceuticals, Inc. – Pipeline By Route of Administration, 2012
Cubist Pharmaceuticals, Inc. – Pipeline Products By Mechanism of Action, 2012
Cubist Pharmaceuticals, Inc. – Recent Pipeline Updates, 2012
Cubist Pharmaceuticals, Inc. - Dormant Developmental Projects,2012
Cubist Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2012
Cubist Pharmaceuticals, Inc., Subsidiaries
Cubist Pharmaceuticals, Inc., Deals Summary
Adolor Reacquires Rights Of ENTEREG From GlaxoSmithKline
Cubist Pharma Acquires 2% Royalty Stream Of CUBICIN From Eli Lilly
FORMA Therapeutics Secures Additional $3 Million In Series B Financing Round
Calixa Therapeutics Secures $30 Million In Series A Financing
Illumigen Biosciences Secures $12 Million In Venture Financing
Illumigen Biosciences Secures $5 Million In Series B Financing
Adolor Enters Into Licensing And Co-Development Agreement With Pfizer
Optimer Pharma Enters Into Co-Promotion Agreement With Cubist Pharma
Evotec Extends Research Agreement With Cubist Pharma
Cubist Pharma Enters Into Co-Development Agreement With Hydra Biosciences
Evotec Enters Into Research Agreement With Cubist Pharma
Beactica Enters Into Co-Development Agreement With Cubist Pharma
FORMA Therapeutics Enters Into Co-Development Agreement With Cubist Pharma
Cubist Pharma Enters Into Co-Development Agreement With Alnylam
Cubist Pharma Enters Into Co-Promotion Agreement With AstraZeneca
deCODE biostructures Enters Into Research Agreement With Cubist Pharma
Cubist Pharma Enters Into Co-Marketing Agreement With Kuhnil Pharma
Adolor Enters Into Co-Promotion Agreement With GlaxoSmithKline
Adolor Amends Collaboration Agreement With GlaxoSmithKline
Motac Neuroscience Enters Into Licensing Agreement With Adolor
Adolor Enters Into Licensing Agreement With Eli Lilly
Cubist Pharma Enters Into Licensing Agreement With Dyax
Cubist Pharma Enters Into Licensing Agreement With Merck
AstraZeneca Enters Into Licensing Agreement With Cubist Pharma
Cubist Pharma Enters Into Licensing Agreement With XTL BioPharma
Adolor Files Registration Statement For Public Offering Of $100 Million
Adolor Completes Public Offering Of $143.75 Million
Cubist Pharma Completes Public Offering Of $120 Million
Cubist Pharma Completes Private Placement Of Convertible Senior Notes Due 2017 For $450 Million
Cubist Pharma Completes Public Offering Of 2.25% Convertible Notes For $350 Million
Cubist Pharma Completes Acquisition Of Adolor For $415 Million
Cubist Pharma Acquires Calixa Therapeutics
Cubist Pharma Acquires Illumigen Biosciences

List of Figures
Cubist Pharmaceuticals, Inc. – Pipeline by Indication, 2012
Cubist Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2012
Cubist Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2012
Cubist Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, 2012
Cubist Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, 2012
Cubist Pharmaceuticals, Inc. - Pipeline By Target, 2012
Cubist Pharmaceuticals, Inc. – Pipeline By Route of Administration, 2012
Cubist Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action, 2012

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos